What Happens When You Stop Weight-Loss Injections? The Plan for Afterwards
After stopping Ozempic, Wegovy or Mounjaro, appetite and weight return for many people. Your time on the injection can be a window: for muscle, steadier blood sugar and a well-stocked nutrient foundation that your body can then sustain on its own.
A weight-loss injection can turn down the volume of your hunger. It cannot practice for you what a life with quieter hunger looks like. Your time on the injection is not a waiting room. It can be your training camp.
Your jeans feel loose. Food is no longer on your mind all day. For the first time in years, your head stays quiet when you walk past a bakery.
And that is exactly when this one question shows up. Quietly, but persistently: What happens when I stop?
Maybe you know stories of people for whom everything came back after they stopped. Maybe you feel the fear that the injection is the only thing that has ever worked for you. That fear is understandable. And it deserves an honest answer.
In this article, you get both: the numbers from the studies on stopping and a plan for the time afterwards. Why your body pushes back after stopping is something I explain in detail in the article Stopping weight-loss injections: avoiding the yo-yo effect. This one is about the practical part. About three pillars you can already build during treatment: muscle, blood sugar and a nutrient foundation.
First, the most important point: semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) are prescription-only medicines. Whether, when and how you stop them or change the dose belongs in a consultation with your doctor. This article deliberately contains no dosages. It is not a recommendation for or against any treatment, and it does not replace medical advice. You can find the bigger picture on these injections in Weight-loss injections: what they can and cannot do.
What to expect in this article
- What happens to weight and metabolism after stopping
- Why your time on the injection can be a window for change
- Muscle as an anchor for basal metabolism and blood sugar
- How steady blood sugar can keep hunger quieter
- Which nutrient foundation matters before stopping
- What the data show on dose reduction and tapering
- Early warning signs to discuss with your doctor
- Eleven answers to frequently asked questions
“It's the only thing that has ever worked.”
I know this pattern very well. A patient came to my practice after many months on a weight-loss injection. A lot of responsibility, little time for herself, years of dieting behind her.
The scale looked good. But the body composition measurement showed that part of the loss came from muscle. Her meals were small and low in protein, and her lab results showed a low vitamin D level.
The turning point was a different question. No longer: When do I stop? But: What needs to be in place before we even talk about stopping? We approached the exit like a project, with strength training, protein first, a calmer eating rhythm and topping up her nutrient foundation. The decision about the medication came only afterwards, and we made it together.
Months later, she told me that the hunger had come back, but that she could now read it. Her weight went up a little and then stayed in a range she can live with comfortably.
I cannot claim causality, but I document the temporal association. The story is condensed and anonymized. A single case proves nothing, and things go differently for other people.
The lesson: The fear of slipping back is not a verdict on you. It is a sign that your plan might still have gaps.
Stopping Ozempic: What happens to your weight?
Let's first look at the number you may be afraid of. Calmly and without drama.
After stopping, a large part of the weight returns on average: around 0.4 kg per month in a large meta-analysis (West 2026).
What randomized trials and meta-analyses establish above all is this: the body responds very reliably to the end of treatment. A particularly comprehensive review of this comes from Oxford.
How quickly weight returns after stopping
Meta-analysis, 37 studies, n=9,341A team at the University of Oxford led by Sam West and Susan Jebb analyzed 37 studies with 9,341 participants who were followed up after their weight-loss medication ended. On average, weight then rose by around 0.4 kg per month, faster than after the end of purely behavioral programs, and cardiovascular and metabolic markers were projected to return to baseline within 1.4 years. What this means for you: without a plan for the time afterwards, you may not only regain kilos, but also lose the improvements in your blood work.
West S, Scragg J, Aveyard P, et al. BMJ. 2026;392:e085304. DOI: 10.1136/bmj-2025-085304The large withdrawal studies paint the same picture. In the STEP 1 extension, participants regained around two thirds of their loss one year after semaglutide and the lifestyle program ended (Wilding 2022). In STEP 4, people who switched to placebo gained 6.9 percent, while those who continued treatment lost a further 7.9 percent (Rubino 2021). After stopping tirzepatide in SURMOUNT-4, the regain was as much as 14.0 percent (Aronne 2024).
Averages are not destinies. In SURMOUNT-4, 16.6 percent of people kept at least 80 percent of their weight loss after switching to placebo (Aronne 2024). A recent review emphasizes that the need for continued treatment varies greatly from person to person, and that some people maintain their weight even without medication (van Bruggen 2026). What this depends on is not yet well understood. And this is exactly where the question of what lies in your own hands begins.
Why does the weight come back? Two forces pull at the same time. The active substance that boosted your satiety is gone. And your body defends its former weight, through more hunger and a more economical energy expenditure. How hunger and satiety interact is something you can read about in Appetite regulation: hunger and satiety.
A review from the Netherlands describes the regain as front-loaded: a large part of it happens in the first months after stopping (Damhof 2026). When treatment ends abruptly, a strong biological pull back meets a sudden lack of satiety support. The team speaks of a critical window.
The weight does not come back because you are weak. It is more likely to come back when only the medication has changed and nothing else. That is exactly where a plan comes in.
And now you know why the plan for the time afterwards does not begin on the day you stop, but long before.
Why is your time on the injection a window?
Do you remember the first weeks on the injection? That unfamiliar silence? Food suddenly stopped calling you.
Many people experience this as relief. Some also find it unsettling: Is this still me? Both are normal. And both are an opportunity.
In one study, freely chosen energy intake fell by 24 percent on semaglutide, and cravings decreased (Blundell 2017).
Fewer cravings, more control over eating
RCT, crossover, n=30A team at the University of Leeds led by John Blundell gave 30 people with obesity twelve weeks of semaglutide or placebo and then swapped the phases. On semaglutide, they ate 24 percent less when they could choose freely, and they reported less hunger and fewer cravings, more control over eating and a lower preference for very high-fat foods. What this means for you: during this time, the voice of food is quieter, and new habits meet less resistance.
Blundell J, Finlayson G, Axelsen M, et al. Diabetes Obes Metab. 2017;19(9):1242-1251. DOI: 10.1111/dom.12932Interpreting this as a window is my reading, not the study's. But it fits a question that a research group in Copenhagen examined very closely: does what you do during treatment make a difference for the time afterwards?
Medication plus exercise: twice the fat loss
RCT, n=195A team at the University of Copenhagen led by Julie Lundgren and Signe Torekov took 195 people with obesity who had lost an average of 13.1 kg on an eight-week diet, and gave them liraglutide, supervised exercise of moderate to high intensity, both, or placebo for one year. The combination reduced body fat percentage about twice as much as either measure alone, and it was the only group to improve long-term blood sugar, insulin sensitivity and fitness. What this means for you: medication and exercise seem not to replace each other, but to complement each other.
Lundgren JR, Janus C, Jensen SBK, et al. N Engl J Med. 2021;384(18):1719-1730. DOI: 10.1056/NEJMoa2028198One year after the end: exercise lasted longer than the medication alone
RCT follow-up, n=109The same group, led by Simon Jensen, examined the participants again one year after all treatments had ended, and 109 came to the follow-up visit. Those who had received liraglutide alone gained 6.0 kg more in the following year than the exercise group, whose weight and body composition remained largely stable. What this means for you: the exercise habits you build during treatment could carry you beyond the end of the medication.
Jensen SBK, Blond MB, Sandsdal RM, et al. EClinicalMedicine. 2024;69:102475. DOI: 10.1016/j.eclinm.2024.102475An honest caveat: liraglutide is an older member of this drug class. Only some of the original participants came to the follow-up. And comparable follow-up data for semaglutide and tirzepatide are still lacking. The direction is remarkable all the same, and it fits what the physiology would suggest.
In my clinical experience, people who trained and reorganized their eating during their time on the injection approach stopping differently. Calmer, better prepared. There are hardly any studies on this feeling. I am only describing what I observe.
Anthroposophic medicine offers an image that I find fitting here: the will lives in the metabolism and in the limbs. The injection dampens the drive to eat. The drive toward movement, strength and a rhythm of your own is something it cannot take over for you. This is a perspective, not a study result. But it explains why training gets so much space in this plan.
Imagine the injection as scaffolding. As long as it stands, you can put up walls in peace. If it comes down before the walls can bear weight, a lot collapses. If it comes down once the walls are standing, more of the house remains. The injection is the scaffolding. You build the house.
And now you know why the best time for the plan afterwards is the time before.
Pillar 1: Why is muscle your anchor for the time afterwards?
The scale shows less. Your jeans are slipping. And yet the case of water feels heavier than it used to.
That is no coincidence. Part of the weight you lose on the injection comes from fat-free mass, which includes muscle. How much that can be and how you can counteract it is described in detail in the article Muscle loss on weight-loss injections. Here the question is a different one: why does muscle in particular help determine what happens after you stop?
Muscle is your largest sugar consumer: when insulin is acting, around 80 percent of glucose uptake in laboratory tests takes place in skeletal muscle (DeFronzo 2009).
Imagine your muscle as a sponge. After a meal, it soaks sugar out of your blood and stores it. The bigger and better trained the sponge, the less sugar stays behind in your blood. Ralph DeFronzo and Devjit Tripathy from San Antonio summarized this central role of skeletal muscle for blood sugar (DeFronzo 2009). So less muscle does not just mean less strength. It can also mean less of a buffer for your blood sugar and a lower basal metabolic rate.
When weight returns, more fat than muscle comes back
Cohort after RCT, n=78Kristen Beavers and colleagues at Wake Forest University followed 78 postmenopausal women for a year beyond a weight-loss program and measured their body composition. During weight loss, 0.26 kg of fat-free tissue was lost for every kilogram of fat, while during regain only 0.12 kg came back for every kilogram of fat. What this means for you: if you lose weight without protecting your muscles and then regain it, you could end up at the same weight with a less favorable ratio of muscle to fat than before.
Beavers KM, Lyles MF, Davis CC, et al. Am J Clin Nutr. 2011;94(3):767-774. DOI: 10.3945/ajcn.110.004895Important: these data come from a diet study, not from a study with weight-loss injections. Whether the same pattern appears after semaglutide or tirzepatide has not yet been well studied. It is mechanistically plausible, but not established.
Protein in a calorie deficit: more fat-free mass, a steadier resting metabolism
Meta-analysis, 24 RCTs, n=1,063Thomas Wycherley and colleagues at the University of South Australia analyzed 24 randomized trials in which people ate the same number of calories and equally little fat, but different amounts of protein. The higher-protein diet preserved an average of 0.43 kg more fat-free mass and cushioned the drop in resting energy expenditure by around 596 kilojoules per day, which is about 140 kilocalories. What this means for you: protein is not a fitness extra, but building material that can support your energy expenditure in the time afterwards.
Wycherley TP, Moran LJ, Clifton PM, Noakes M, Brinkworth GD. Am J Clin Nutr. 2012;96(6):1281-1298. DOI: 10.3945/ajcn.112.044321What you can do for your muscles
The direction is clear, the details are individual. Strength training can send the signal: I still need this muscle. Train the large muscle groups against resistance, meaning legs, glutes, back and chest. At every meal, plan your protein source first. And before any decision about stopping, have your body composition measured so that you can see where you stand.
How much training and protein count as a minimum is something I have put together in the article on protecting your muscles on the injection. You can find more background in Strength training after 40 and Strength training for insulin resistance.
Building muscle on the injection is not an optional extra. It is your insurance for the time when your appetite comes back. Every bit of muscle is one more sponge for your blood sugar.
And now you know why muscle comes first in this plan.
Pillar 2: How can steady blood sugar keep hunger quieter?
Do you know that afternoon slump? Two or three hours after lunch, you get jittery. Your concentration crumbles. And suddenly the cookie jar is the center of the world.
Many people see this as weakness. Often something else is behind it: a blood sugar curve that first shoots steeply upward and then drops below its starting level.
In a study of 1,070 people, blood sugar dips two to three hours after eating predicted more hunger and more calories over the following 24 hours (Wyatt 2021).
Not the peak, but the dip afterwards makes you hungry
Cohort, n=1,070A team from London, Leeds and Boston led by Patrick Wyatt and Ana Valdes fitted 1,070 healthy people with glucose sensors and recorded over 8,600 standardized and more than 71,000 freely chosen meals. The further blood sugar fell below baseline two to three hours after eating, the greater the hunger, the sooner the next meal came and the more energy was consumed over the following 24 hours. What this means for you: once you have stopped, steady blood sugar could give you back part of the satiety that the medication used to boost.
Wyatt P, Berry SE, Finlayson G, et al. Nat Metab. 2021;3(4):523-529. DOI: 10.1038/s42255-021-00383-xAn honest caveat: the associations were statistically clear, but rather small. The participants were healthy and were not using weight-loss injections. Applying this to the time after stopping is a hypothesis, biologically plausible, but not specifically tested.
After stopping, this topic gains extra weight. A meta-analysis from Taiwan of 18 randomized trials with 3,771 participants showed that in people with obesity, weight, waist circumference, blood pressure, fasting blood sugar and long-term blood sugar rose again on average after GLP-1 therapy ended (Tzang 2025). So metabolism does not just slide back on the scale, but in the blood as well.
Vegetables and protein first: flatter curves
RCT, crossover, n=15Alpana Shukla and colleagues at Weill Cornell Medicine in New York had 15 people with prediabetes eat the same meal in a different order on three days. When protein and vegetables came ten minutes before the carbohydrates, the sugar peaks were more than 40 percent lower, the area under the glucose curve was 38.8 percent smaller and the curve stayed stable. What this means for you: not only what you eat, but also the order you eat it in, can calm your curve.
Shukla AP, Dickison M, Coughlin N, et al. Diabetes Obes Metab. 2019;21(2):377-381. DOI: 10.1111/dom.13503The second simple lever is movement after eating. A meta-analysis of seven randomized crossover trials from the University of Limerick found that short, light walking breaks instead of prolonged sitting clearly lowered blood sugar and insulin after eating, more than simply standing up (Buffey 2022). Your muscle then takes the sugar straight from your blood, on the go, so to speak.
Nervous system
The hunger and satiety centers in the brain respond to falling blood sugar. A deep dip after eating can act like an alarm that sends you to your next meal.
Hormonal system
Insulin, glucagon and your body's own GLP-1 steer the curve. Protein and fiber can stimulate your own satiety hormone response, which is mechanistically plausible and the topic of the article Boosting GLP-1 naturally.
Metabolism
Muscle is the largest consumer of sugar. Working muscles open additional transport routes into the cell, partly independent of insulin. That is why movement after eating counts twice.
Immune system
Belly fat is metabolically active and can release inflammatory messengers. Silent inflammation can disrupt insulin and satiety signals, more on this in Silent inflammation and weight.
What can make your blood sugar steadier
Three directions, no rigid rules. First: protein and vegetables first, carbohydrates last. Second: after your largest meal, walk for a few minutes instead of heading straight for the sofa. Third: if you want to know how your body responds to your favorite foods, a trial phase with a glucose sensor can be very revealing. How that works is described in the article Blood sugar and weight loss: the CGM sensor. You can find more on order and combinations in Avoiding blood sugar spikes.
Cravings are not always a question of character. Sometimes they are the echo of a glucose curve. If you smooth the curve, you may have to fight against yourself less.
And now you know why your blood sugar gets its own pillar in this plan.
Pillar 3: What nutrient foundation does your body need after the injection?
On the injection, eating less feels easy. Sometimes almost too easy. A yogurt in the morning, half a plate in the evening, and you are full.
The problem: less food also means less building material. Less protein, fewer vitamins, fewer minerals. And a body with empty stores starts at a disadvantage in the phase when the appetite comes back.
In an analysis of more than 461,000 people, 22.4 percent were diagnosed with a nutrient deficiency within a year of starting GLP-1 therapy (Butsch 2025).
More than one in five with a diagnosed nutrient deficiency
Cohort, retrospective, n=461,382A team led by W. Scott Butsch at the Cleveland Clinic analyzed claims data from 461,382 adults who had newly started a GLP-1 medication, most of them with type 2 diabetes. After six months, 12.7 percent had been diagnosed with a nutrient deficiency, and after twelve months 22.4 percent, most commonly vitamin D deficiency at 13.6 percent. What this means for you: nutrients belong in your planning before you think about stopping, not only afterwards.
Butsch WS, Sulo S, Chang AT, et al. Obes Pillars. 2025;15:100186. DOI: 10.1016/j.obpill.2025.100186An honest caveat: claims data only show what was diagnosed and documented. Employees of a manufacturer of nutrition products were also involved in the study. So the figure is a warning sign, not an exact risk.
Four professional societies: nutrition is part of therapy
Review, expert advisoryA panel led by Dariush Mozaffarian of Tufts University summarized, on behalf of four US professional societies in lifestyle medicine, nutrition and obesity medicine, what matters most around GLP-1 medications. As challenges, they name nutrient deficiencies due to lower calorie intake, loss of muscle and bone, and weight regain after treatment ends. As priorities, they name preventing deficiencies and preserving muscle and bone through strength training and appropriate nutrition. What this means for you: the experts themselves name nutrition for the time after stopping as a field that needs more research, but good foundations are already possible today.
Mozaffarian D, Agarwal M, Aggarwal M, et al. Am J Clin Nutr. 2025;122(1):344-367. DOI: 10.1016/j.ajcnut.2025.04.023In my clinical experience, three things in particular tend to fall short on the injection: protein, fiber and micronutrients. That is why, before a decision about stopping, I typically look at vitamin D, vitamin B12, iron status including ferritin, and blood sugar and long-term blood sugar, plus other values depending on the medical history. This is my practice, not a standard derived from studies.
When it comes to the food itself, quality comes before quantity. Real, minimally processed foods with protein and fiber can keep you full for longer and support your body's own satiety signals. You can read why that is in the article Unprocessed food and satiety. And if your vitamin D is low, Taking vitamin D correctly explains what matters when supplementing.
A plan for the time afterwards does not begin with giving things up. It begins with filling up. A body with full stores starts with a reserve instead of a deficit.
And now you know why lab values and your plate belong in this plan, not just dumbbells.
Stopping, reducing or tapering: What do the data say?
Maybe you are hoping for a gentle exit. Not from a hundred to zero, but step by step. That is an understandable wish. The research on it, however, still has gaps.
In SURMOUNT-MAINTAIN, people on a reduced maintenance dose kept more of their weight loss than after switching to placebo, but less than with unchanged continuation (Horn 2026).
A lower dose instead of zero: what happened
RCT, n=378Deborah Horn and colleagues in the US treated people with obesity with tirzepatide for 60 weeks and then randomly assigned 378 of them to unchanged continuation, a lower maintenance dose or placebo, each for another year. From the start of the study to week 112, average weight loss was 21.9 percent with continuation, 16.6 percent with the reduced dose and 9.9 percent with placebo, and 8, 25 and 67 percent respectively received rescue treatment for regaining more than half of their loss. What this means for you: between carrying on and stopping, there are middle paths whose benefit can vary greatly from person to person, and the study was funded by the manufacturer.
Horn DB, Aronne LJ, Wharton S, et al. Lancet. 2026;407(10545):2305-2318. DOI: 10.1016/S0140-6736(26)00656-2And classic tapering, meaning lowering the dose step by step all the way to zero? Here the evidence is thin. The Dutch review notes that a reduced maintenance treatment can soften the regain. Whether a structured taper makes it easier to stop altogether, on the other hand, is still unknown (Damhof 2026). There is no established schedule for it so far.
What you can plan well, on the other hand, is attention. The same research group suggests using early changes in appetite, satiety, thoughts about food, weight trend, waist circumference and metabolic markers as early warning signs (van Bruggen 2026). This, too, still needs to be confirmed in studies. As a basis for conversations with your doctor, it is valuable all the same.
Hunger and thoughts about food
Are your thoughts circling around food more often again? Write it down before the scale reacts.
Waist circumference
A tape measure can show changes around your belly that barely register on the scale yet.
Weight trend
What counts is not the single day, but the direction over several weeks.
Metabolic markers
Blood sugar, long-term blood sugar and blood pressure, especially if you have type 2 diabetes.
It makes sense to agree with your doctor beforehand on which signals will prompt the two of you to decide anew. That way, fear turns into a plan B.
Stopping is not a date in the calendar. It is a phase with checkpoints and a plan B. And continuing treatment is not a failure, but a medical decision, just as it is with high blood pressure.
And now you know why the question is not only whether you stop, but how well supported you are when you do.
Freedom does not mean never needing anything again
Freedom means being able to make the decision about the injection without fear. Because you know what your body can carry. Because you can read hunger instead of running from it. And because you have built a body that is strong enough for what you want to do with your life.
What does a plan for the time after weight-loss injections look like?
Enough theory. Maybe you are sitting on the sofa with your phone right now, asking yourself: So what exactly do I do now?
A plan in three phases can give you orientation. These are directions, not recipes. The finer details belong in individual guidance.
Building the foundation
- Make strength training a firm part of everyday life
- Plan protein first at every meal
- Practice your eating rhythm and food order
- Have body composition and nutrient status measured
Deciding together
- Weigh continuing, reducing or stopping with your doctor
- Agree on early warning signs and thresholds beforehand
- Have the first months closely supervised
Letting everyday life carry you
- Training stays, even when your weight is where you want it
- Keep up your blood sugar rhythm
- Protect your sleep, because lack of sleep can make you hungry
- Check your values and waist circumference regularly
How closely sleep and hunger are connected is something you can read about in Sleep and weight loss.
Your three levers for this week
Give your muscles a signal
Put two set strength training sessions in your calendar, as binding as a doctor's appointment. And at every meal, plan the protein source first, then the rest.
Smooth your glucose curve
Eat vegetables and protein before the carbohydrates. After the largest meal of the day, walk briskly for a few minutes instead of staying seated straight away.
Measure your starting point
Before any decision about stopping, have your body composition and nutrient status checked. And discuss with your doctor which early warning signs you will watch together.
If you would like to do more than read and get started right away: below this article you will find the option to book an appointment.
Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) are prescription-only medicines. Do not stop them on your own, and do not change the dose or rhythm without consulting your doctor. If you have type 2 diabetes, your blood sugar can rise again after stopping, and your diabetes treatment may then need to be adjusted. If you are planning a pregnancy, are pregnant or are breastfeeding, separate rules apply that you should discuss with your doctor. This article is for information only and does not replace a medical examination, diagnosis or treatment.
Frequently asked questions about stopping weight-loss injections
Will I automatically regain weight after stopping Ozempic?
Not automatically, but on average a large part of the weight returns. In the STEP 1 extension, participants regained around two thirds of their loss one year after stopping semaglutide (Wilding 2022). A meta-analysis of 37 studies found an average regain of around 0.4 kg per month (West 2026). But averages are not destinies: in SURMOUNT-4, roughly one in six people kept at least 80 percent of their loss after switching to placebo (Aronne 2024). A plan built on muscle, steady blood sugar and a good nutrient foundation can improve your starting position.
How quickly does the weight come back after stopping?
A large part of the regain happens early, in the first months after stopping. One review describes the course as front-loaded and the first period afterwards as a critical window (Damhof 2026). In a meta-analysis, the average regain was around 0.4 kg per month, faster than after the end of purely behavioral programs (West 2026). That is why it is worth building your plan before stopping and having the first period afterwards closely supervised.
Can I taper off the weight-loss injection instead of stopping abruptly?
Whether and how is something you decide together with your doctor. For tirzepatide, there is a randomized trial on this: people who reduced to a lower maintenance dose after losing weight kept more of their weight loss on average than after switching to placebo, but less than with unchanged continuation (Horn 2026). Whether gradually tapering down to zero makes it easier to stop altogether, on the other hand, has not yet been studied (Damhof 2026). So never change the dose or rhythm on your own.
Can exercise help me keep the weight off after stopping?
The data suggest that exercise during treatment can make a difference for the time afterwards. In a study from Copenhagen, people gained 6.0 kg more in the year after ending treatment with liraglutide alone than after ending a supervised exercise program (Jensen 2024). Those who had combined medication and exercise were clearly more likely to maintain a weight loss of at least 10 percent one year after treatment ended than those who had received placebo. Liraglutide is an older member of this drug class, and such follow-up data are still lacking for semaglutide and tirzepatide. Strength training can also protect the muscle that supports your basal metabolic rate and your blood sugar.
How much protein do I need before and after stopping?
Protein is a central building block because it can protect muscle and help you feel full. In a meta-analysis of 24 randomized trials, a higher-protein diet in a calorie deficit preserved an average of 0.43 kg more fat-free mass and cushioned the drop in resting energy expenditure (Wycherley 2012). How much is right for you depends on your body composition, age, training and kidney function. You can find specific targets per kilogram of body weight in the article on protecting your muscles on weight-loss injections. In everyday life, it can be easier to plan your protein source first at every meal.
What does blood sugar have to do with hunger after stopping?
Blood sugar dips after eating can drive hunger. In a study of 1,070 participants with glucose sensors, drops two to three hours after a meal predicted more hunger, an earlier next meal and more energy consumed over the following 24 hours (Wyatt 2021). In people with obesity, fasting blood sugar and long-term blood sugar also rose again on average after GLP-1 therapy ended (Tzang 2025). A steadier curve through meal order, protein, fiber and movement after eating can therefore be one building block against returning hunger.
Which blood values should I have checked before stopping?
That depends on your medical history, but taking stock makes sense. In an analysis of more than 461,000 people, 22.4 percent were diagnosed with a nutrient deficiency within a year of starting GLP-1 therapy, most commonly vitamin D deficiency (Butsch 2025). Four US professional societies name preventing nutrient deficiencies as a priority during therapy (Mozaffarian 2025). In my practice, I typically look at vitamin D, vitamin B12, iron status including ferritin, and blood sugar and long-term blood sugar, plus other values depending on the situation. What makes sense for you is best clarified in a consultation.
What happens if I stop Ozempic when I have type 2 diabetes?
With type 2 diabetes, blood sugar can rise again after stopping, which is why this step always belongs in medical hands. In a meta-analysis of randomized trials, the long-term blood sugar marker HbA1c rose by an average of 0.65 percentage points in people with type 2 diabetes after GLP-1 therapy ended (Tzang 2025). In Germany, Ozempic is approved for the treatment of type 2 diabetes, and for weight management there is Wegovy, a preparation with the same active substance. If the medication is stopped, your diabetes treatment may need to be adjusted. So always plan this step together with your diabetes care team.
After stopping, do I mainly regain fat, or muscle too?
This has not yet been well studied for GLP-1 medications, but data from diet studies call for attention. In a follow-up of 78 postmenopausal women, 0.26 kg of fat-free tissue was lost for every kilogram of fat during weight loss, while only 0.12 kg came back for every kilogram of fat during regain (Beavers 2011). So if you regain weight, you could regain more fat than muscle. Whether the same applies after semaglutide or tirzepatide is an open question. Strength training and enough protein before and after stopping are therefore sensible building blocks.
When should I start preparing to stop?
Ideally long before stopping, in other words during treatment. During this time, hunger and cravings are often much quieter: in a study with semaglutide, freely chosen energy intake fell by 24 percent, cravings decreased and control over eating increased (Blundell 2017). You can use this window to practice training, protein and a calm eating rhythm. If you only start on the day you stop, you enter the phase with the strongest headwind.
Is it a failure if I still need the injection?
No. The authors of the STEP 1 extension see their data as confirmation that obesity is a chronic condition and that continued treatment may be needed to maintain weight and health (Wilding 2022). How much treatment someone needs in the long term varies greatly from person to person (van Bruggen 2026). Whether you continue treatment, reduce it or stop is a medical decision, not a moral one. The plan built on muscle, blood sugar and a nutrient foundation is worthwhile on every one of these paths.
More articles on weight loss
- Understanding weight holistically: all the building blocks at a glance
- Weight-loss injections: what they can and cannot do
- Weight-loss injections: the GLP-1 mechanism
- Mounjaro and tirzepatide
- Weight-loss injections: putting side effects into context
- Weight-loss injections and muscle loss: the risk
- Muscle loss on weight-loss injections: protecting your muscles
- Stopping weight-loss injections: avoiding the yo-yo effect
- Boosting GLP-1 naturally
- Insulin resistance and weight loss
- Recognizing and reversing insulin resistance
- Leptin and insulin: the weight hormones
- Appetite regulation: hunger and satiety
- Cravings: where they come from
- Avoiding blood sugar spikes: order, combination, timing
- Blood sugar and weight loss: the CGM sensor
- Why am I not losing weight even though I eat little?
- Boosting your metabolism: what counts
- Sleep and weight loss
- Losing weight during menopause
- Silent inflammation and weight
- The calorie myth: quality over quantity
- Unprocessed food and satiety
- The breast milk puzzle: growth despite few calories
Connections to other topics
Nutrition · Protein
How much protein you need per day and when more can make sense.
Nutrition · Satiety
Feeling full is a signal: how protein and body awareness work together.
Sport · Strength training after 40
Why muscle can be your most important longevity organ.
Sport · Insulin resistance
Muscle as a blood sugar buffer in diabetes and insulin resistance.
Nutrition · Glucose sensor
14 days with a sensor: reorganizing your diet with real data.
Supplements · Vitamin D
Why vitamin D should be considered together with magnesium and K2.
Sources
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. DOI: 10.1111/dom.14725 · PMID: 35441470 [RCT, extension, n=327]
- Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425. DOI: 10.1001/jama.2021.3224 · PMID: 33755728 [RCT, n=803]
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. DOI: 10.1001/jama.2023.24945 · PMID: 38078870 [RCT, n=670]
- West S, Scragg J, Aveyard P, et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ. 2026;392:e085304. DOI: 10.1136/bmj-2025-085304 · PMID: 41500720 [Meta-analysis, 37 studies, n=9,341]
- Tzang CC, Wu PH, Luo CA, et al. Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis. EClinicalMedicine. 2025;90:103680. DOI: 10.1016/j.eclinm.2025.103680 · PMID: 41399474 [Meta-analysis, 18 RCTs, n=3,771]
- Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242-1251. DOI: 10.1111/dom.12932 · PMID: 28266779 [RCT, crossover, n=30]
- Lundgren JR, Janus C, Jensen SBK, et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. N Engl J Med. 2021;384(18):1719-1730. DOI: 10.1056/NEJMoa2028198 · PMID: 33951361 [RCT, n=195]
- Jensen SBK, Blond MB, Sandsdal RM, et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. EClinicalMedicine. 2024;69:102475. DOI: 10.1016/j.eclinm.2024.102475 · PMID: 38544798 [RCT, follow-up, n=109]
- Beavers KM, Lyles MF, Davis CC, et al. Is lost lean mass from intentional weight loss recovered during weight regain in postmenopausal women? Am J Clin Nutr. 2011;94(3):767-774. DOI: 10.3945/ajcn.110.004895 · PMID: 21795437 [Cohort, follow-up of an RCT, n=78]
- Wycherley TP, Moran LJ, Clifton PM, Noakes M, Brinkworth GD. Effects of energy-restricted high-protein, low-fat compared with standard-protein, low-fat diets: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2012;96(6):1281-1298. DOI: 10.3945/ajcn.112.044321 · PMID: 23097268 [Meta-analysis, 24 RCTs, n=1,063]
- DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 2009;32(Suppl 2):S157-S163. DOI: 10.2337/dc09-S302 · PMID: 19875544 [Review, pathophysiology]
- Wyatt P, Berry SE, Finlayson G, et al. Postprandial glycaemic dips predict appetite and energy intake in healthy individuals. Nat Metab. 2021;3(4):523-529. DOI: 10.1038/s42255-021-00383-x · PMID: 33846643 [Cohort, n=1,070]
- Shukla AP, Dickison M, Coughlin N, et al. The impact of food order on postprandial glycaemic excursions in prediabetes. Diabetes Obes Metab. 2019;21(2):377-381. DOI: 10.1111/dom.13503 · PMID: 30101510 [RCT, crossover, n=15]
- Buffey AJ, Herring MP, Langley CK, Donnelly AE, Carson BP. The Acute Effects of Interrupting Prolonged Sitting Time in Adults with Standing and Light-Intensity Walking on Biomarkers of Cardiometabolic Health in Adults: A Systematic Review and Meta-analysis. Sports Med. 2022;52(8):1765-1787. DOI: 10.1007/s40279-022-01649-4 · PMID: 35147898 [Meta-analysis, 7 crossover RCTs]
- Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344-367. DOI: 10.1016/j.ajcnut.2025.04.023 · PMID: 40450457 [Review, expert advisory from four professional societies]
- Butsch WS, Sulo S, Chang AT, et al. Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: A retrospective observational study. Obes Pillars. 2025;15:100186. DOI: 10.1016/j.obpill.2025.100186 · PMID: 40584822 [Cohort, retrospective, n=461,382]
- Horn DB, Aronne LJ, Wharton S, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2026;407(10545):2305-2318. DOI: 10.1016/S0140-6736(26)00656-2 · PMID: 42119587 [RCT, n=378, manufacturer-funded]
- Damhof MA, van Bruggen FH, van Roon EN. Early Weight Regain After GLP-1 Receptor Agonist Discontinuation: Mechanisms and Implications for Treatment De-Escalation Strategies. Diabetes Obes Metab. 2026;28(10):8769-8776. DOI: 10.1111/dom.71075 · PMID: 42396734 [Review]
- van Bruggen FH, Damhof MA, van Roon EN. Adaptive maintenance after incretin-induced weight loss: Moving beyond the continue-or-stop paradigm. Obes Pillars. 2026;20:100327. DOI: 10.1016/j.obpill.2026.100327 · PMID: 42733607 [Review, narrative perspective]